In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, Epizyme Inc. (NASDAQ:EPZM) reported interim data from a cohort of 31 evaluable patients with SWI/SNF related matrix associated actin dependent
In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, Epizyme Inc. (NASDAQ:EPZM) reported interim data from a cohort of 31 evaluable patients with SWI/SNF related matrix associated actin dependent